Risperidone
In brief
- In our pharmacy, you can buy risperidone without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Risperidone is intended for the treatment of schizophrenia, bipolar disorder (acute manic or mixed episodes) and irritability associated with autism. It is an atypical antipsychotic that primarily antagonises dopamine D2 and serotonin 5‑HT2A receptors.
- The usual dose for adults is 2–8 mg daily (often started at 1–2 mg/day and titrated). For acute mania typical doses are 2–6 mg/day; elderly or frail patients usually start lower (e.g. 0.5–1 mg/day). Long‑acting injectable regimens commonly use 25–50 mg every 2 weeks.
- The drug is available as oral tablets, orally disintegrating (Melt) tablets, oral solution and as long‑acting intramuscular depot injections.
- Some effects such as sedation or reduced agitation may begin within a few hours; antipsychotic benefits often start within days, with more substantial improvement over 1–4 weeks.
- Oral risperidone is usually taken once daily and its clinical effects last about 24 hours; injectable depot formulations provide therapeutic coverage for 2 weeks (Risperdal Consta) or up to a month with other long‑acting products.
- Do not consume alcohol while taking risperidone — alcohol can increase drowsiness, dizziness and the risk of orthostatic hypotension and other side effects.
- The most common side effect is drowsiness (somnolence).
- Would you like to try risperidone without a prescription?
Basic risperidone information
- INN (international nonproprietary name): Risperidone
- Brand names available in the United Kingdom: Risperdal, Risperdal Consta (long-acting injection); generic risperidone
- ATC code: N05AX08
- Forms and dosages: tablets 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg; orodispersible tablets; oral solution 1 mg/ml; long-acting depot injection 25 mg, 37.5 mg, 50 mg
- Manufacturers in the United Kingdom: Janssen-Cilag (Risperdal) and several generic manufacturers
- Registration status in the United Kingdom: Licensed by the MHRA; prescription-only medicine
- OTC / Rx classification: Prescription-only medicine (POM)
Legal status and availability in the UK
Risperidone is a prescription-only medicine (POM) in the UK.
In our online pharmacy, risperidone is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Licensed indications and UK approvals
MHRA‑approved uses in adults and children
Risperidone is licensed in the UK for treatment of schizophrenia in adults and adolescents where indicated by specialist care.
It is licensed for acute mania and maintenance treatment of bipolar disorder in adults.
Short‑term management of severe behavioural disturbances in dementia has historically involved antipsychotics with strong cautions and is restricted due to increased mortality risk.
In paediatric practice risperidone may have licensed uses for irritability associated with autism spectrum disorder in certain age groups, with dose limits and specialist oversight.
Common off‑label uses and cautions
Off‑label practices can include adjunctive use in treatment‑resistant depression or for challenging behaviours where non‑drug options have been exhausted.
Any off‑label use should be documented with a clear clinical rationale and informed consent from the patient or carer.
Shared care agreements are commonly used when care moves from secondary to primary settings, particularly for depot switching.
Forms, presentations and dosing options
Oral tablets and oral solution dosing
Risperidone tablets are typically available in 0.5 mg, 1 mg and 2 mg strengths and are taken once or twice daily depending on prescriber instructions.
Oral solution is useful for patients with swallowing difficulties and is dosed using an accurate oral syringe according to milligram per millilitre instructions.
Long‑acting injectable regimen and community administration
Long‑acting risperidone microsphere injections are given by trained professionals in clinics at specified intervals and often require overlap with oral risperidone during initiation.
Depot switching protocols commonly require a loading schedule or an oral overlap period until steady state is achieved with the depot formulation.
| Form | Strength | Typical starting dose | Typical maintenance dose |
|---|---|---|---|
| Tablet | 0.5 mg, 1 mg, 2 mg | 1–2 mg daily, titrate | 2–6 mg daily depending on response |
| Oral solution | 1 mg/mL | Individualised by weight and swallowing needs | As per tablet equivalent |
| Depot injection | 25/37.5/50 mg | Initial loading per SPC; often overlap with oral for 3 weeks | Administration every 2 weeks or monthly depending on product |
Exact regimens must follow the SPC and the prescribing clinician’s instructions.
How to use: administration, missed dose, overdose
Practical instructions for patients and carers
Swallow tablets whole with water; do not crush unless the prescriber or pharmacist has authorised an alternative formulation.
Use the provided measuring syringe for oral solution and ensure accurate dosing according to the prescription label.
Long‑acting injections must be administered by a trained professional in clinic or community settings; do not attempt self‑administration unless specifically trained and authorised.
- Take tablets at the same time each day to support adherence.
- Measure liquid doses carefully and return the syringe to the pharmacy if lost or damaged.
- Keep a record of depot appointments and contact the clinic promptly if an appointment cannot be kept.
Missed dose and overdose
If a single oral dose is missed, take it as soon as remembered on the same day and return to the usual schedule the next day unless otherwise advised.
If a depot appointment is missed, contact the clinic immediately; reinstate oral risperidone if advised until the depot is given to avoid relapse.
Overdose signs include marked drowsiness, severe low blood pressure, respiratory depression and extrapyramidal signs.
Seek urgent medical attention in case of suspected overdose and bring the medicine packaging or prescription with you.
In severe cases call 999 or go to A&E with the pack, and contact local mental health crisis teams if behavioural disturbance is present.
Contraindications, warnings and cautions
Absolute contraindications
- Known hypersensitivity to risperidone or any excipients.
Important cautions
| Caution | Required monitoring/action |
|---|---|
| Cardiac history / QT prolongation risk | Review ECG and avoid co‑prescribing QT‑prolonging drugs where possible. |
| Stroke or TIA in elderly with dementia | Avoid where possible; increased mortality risk must be discussed and documented. |
| Neuroleptic malignant syndrome risk | Discontinue and seek urgent medical care if suspected. |
| Hyperprolactinaemia | Monitor for amenorrhoea, galactorrhoea, sexual dysfunction; measure prolactin if symptomatic. |
| Metabolic effects | Baseline and ongoing weight, glucose and lipid monitoring. |
| Pregnancy and breastfeeding | Use only if benefits justify risks; consult obstetric psychiatry services. |
Side effects: frequency, management and monitoring
Common and bothersome adverse effects
| Frequency | Adverse effects | Management |
|---|---|---|
| Common | Drowsiness, weight gain, increased appetite, constipation | Adjust dose timing for sedation, diet/exercise support, laxatives for constipation. |
| Common | Extrapyramidal symptoms, akathisia | Report promptly; consider dose reduction or adjunctive anticholinergic under clinical advice. |
| Rare but serious | Hyperglycaemia, tardive dyskinesia, neuroleptic malignant syndrome, prolonged QT | Urgent clinical review and stopping drug may be required; monitor ECG and metabolic parameters. |
When to seek clinical review and monitoring schedule
Baseline checks should include weight, BMI, fasting glucose or HbA1c, fasting lipids and blood pressure.
Repeat metabolic monitoring at 3 months and periodically thereafter, and at least annually for stable patients.
ECG should be considered where cardiac risk factors or interacting medications are present.
Measure prolactin if patients develop sexual dysfunction, menstrual disturbance or unexplained galactorrhoea.
Encourage patients to report movement disorders or new sedation as soon as they appear.
Drug interactions and medicines to avoid
Major pharmacokinetic and pharmacodynamic interactions
Risperidone levels can be affected by CYP2D6 inhibitors and CYP3A4 modulators, altering efficacy and side‑effect risk.
Additive CNS depression occurs when combined with benzodiazepines, opioids or alcohol; counsel to avoid alcohol.
Co‑administration with QT‑prolonging drugs increases cardiac risk and should trigger ECG monitoring or avoidance.
Concomitant use of dopaminergic agents or metoclopramide can modify extrapyramidal side effects and requires caution.
Interaction checks and counselling points
- Verify full medication history including OTC and herbal medicines before dispensing.
- Check for CYP2D6 inhibitors such as fluoxetine and paroxetine and adjust monitoring accordingly.
- Advise patients to avoid alcohol and report new prescriptions from other clinicians.
- Use a drug interaction checker and consult BNF or MHRA guidance for complex cases.
Pregnancy, breastfeeding, contraception and fertility
Risk assessment and counselling for women of childbearing age
Exposure to antipsychotics late in pregnancy can cause neonatal withdrawal or extrapyramidal signs in the newborn.
Shared decision making is vital; specialist antenatal psychiatry input should guide continuation or switching of therapy.
Advise effective contraception where teratogenic risk or hyperprolactinaemia may affect fertility or menstrual function.
Breastfeeding and neonatal considerations
Risperidone is excreted in breast milk and may cause sedation or poor feeding in infants; weigh maternal benefit against infant risk.
If breastfeeding is continued, monitor the infant for excessive sleepiness and feeding problems and consult paediatric services if concerned.
Document counselling and any agreed shared care plan clearly in the record.
Storage, handling and disposal
Storage of risperidone products
- Store most risperidone tablets at room temperature away from moisture and light.
- Oral solutions should be labelled with storage instructions and kept in original packaging.
- Depot injections handled per SPC; some depot presentations may require specific handling but most are stored at controlled room temperature.
Patient advice for home storage and safe disposal
Keep medicines in their original pack, away from direct heat and moisture and out of reach of children.
Return unused medicines and sharps to a pharmacy for safe disposal via the NHS medicine return scheme.
If injections are administered at home, advise on sharps disposal via local council or pharmacy takeback points.
Alternatives, switches and comparator drugs
Common alternatives in class and switching rationale
Other antipsychotics commonly used in the UK include olanzapine, quetiapine, aripiprazole and haloperidol.
Long‑acting alternatives include paliperidone palmitate and aripiprazole LAI for patients needing depot formulations.
Reasons to switch include inadequate efficacy, intolerable metabolic effects, movement disorders or adherence challenges.
Switching notes
| Drug | Key pros | Key cons / monitoring |
|---|---|---|
| Olanzapine | Effective for psychosis and mania | High metabolic risk; monitor weight and glucose |
| Aripiprazole | Lower prolactin and metabolic effects | Activation or akathisia in some patients |
| Paliperidone palmitate | Depot option with monthly to 3‑monthly dosing | Requires injection clinic and monitoring |
Cross‑titration and documenting shared care arrangements are essential when switching antipsychotics.
Liaise with community mental health teams when arranging depot changes and schedule appointments to avoid gaps in therapy.
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Sheffield | England | 9–21 days |
| Bristol | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Leicester | England | 9–21 days |
| Coventry | England | 9–21 days |
| Nottingham | England | 9–21 days |
Final notes for patients
Patients should always bring medicine packs to appointments and report any new side effects promptly to their pharmacist or prescriber.